

## **Aspirus Practice Guideline**

**Topic:** Treatment of Patients With Schizophrenia

**Date:** Initial Guideline Adoption: September 17<sup>th</sup>, 2020  
Last QIAC Review/Approval: September 27<sup>th</sup>, 2022

**Primary Source:** American Psychiatric Association

**Link to Guideline:**

[http://psychiatryonline.org/pb/assets/raw/sitewide/practice\\_guidelines/guidelines/schizophr enia.pdf](http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/schizophr enia.pdf)

The Practice Guideline for the Treatment of Patients with Schizophrenia was adopted as the Aspirus Clinical Practice Guideline with the following modifications:

**Aspirus Comments/Modifications of Guideline:**

Aspirus is proposing the removal of Molindone from the guidelines due to the discontinuation of its manufacture. Abilify is added to the list of medications used in treatment for this disorder.